ArticleInternational journal of epidemiology2025
Age and gender profiles of HIV infection burden and viraemia: novel metrics for HIV epidemic control in African populations with high antiretroviral therapy coverage.
Article in International journal of epidemiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- HIV drug resistance during antiretroviral therapy scale-up in Uganda, 2012-19: a population-based, longitudinal study.The Lancet. Microbe · 2025Article
Corrections and comments
- Update of
Authors and funding
21 authors.
Funding
Abstract
introductionTo prioritize and tailor interventions for ending AIDS by 2030 in Africa, it is important to characterize the population groups in which human immunodeficiency virus (HIV) viraemia is concentrating.
methodsWe analysed HIV testing and viral load data collected between 2013 and 2019 from the open, population-based Rakai Community Cohort Study in Uganda, to estimate HIV seroprevalence and population viral suppression over time by gender, 1-year age bands, and residence in inland and fishing communities. All estimates were standardized to the underlying source population by using census data. We then assessed 95-95-95 targets in their ability to identify the populations in which viraemia is concentrated.
resultsFollowing the implementation of Universal Test and Treat, the proportion of individuals with viraemia decreased from 4.9% (4.6%-5.3%) in 2013 to 1.9% (1.7%-2.2%) in 2019 in inland communities and from 19.1% (18.0%-20.4%) in 2013 to 4.7% (4.0%-5.5%) in 2019 in fishing communities. Viraemia did not concentrate in the age and gender groups furthest from achieving 95-95-95 targets. Instead, in both inland and fishing communities, women aged 25-29 years and men aged 30-34 years were the 5-year age groups that contributed most to population-level viraemia in 2019, despite these groups being close to or having already achieved 95-95-95 targets.
conclusionThe 95-95-95 targets provide a useful benchmark for monitoring progress towards HIV epidemic control, but do not contextualize underlying population structures and so may direct interventions towards groups that represent a marginal fraction of the population with viraemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.